Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Core Viewpoint - Genprex has received a Notice of Acceptance from IP Australia for a patent application related to Reqorsa® Gene Therapy in combination with PD-L1 antibodies for cancer treatment, which will enhance its intellectual property portfolio and protect its therapeutic combination currently in the Acclaim-3 clinical trial [1]. Patent Development - The patent application claims the use of Reqorsa® Gene Therapy with PD-L1 antibodies, which has already been granted in other countries [1]. - A granted patent will provide exclusivity in Australia, preventing competitors from manufacturing, using, or selling the drug combination [1]. - Genprex is pursuing additional patent applications in key international markets, including Europe, Canada, Brazil, China, and Israel, to safeguard its innovations [1]. Clinical Trial Updates - Genprex has opened an additional clinical trial site for the Acclaim-3 trial at the University of Kentucky to expand patient reach and expedite enrollment [1]. - The Acclaim-3 trial is a Phase 1/2 study evaluating the combination of REQORSA and Genentech's Tecentriq® in patients with extensive stage small cell lung cancer (ES-SCLC) [1]. - The Phase 2 expansion study aims to enroll approximately 50 patients, with the primary endpoint being the 18-week progression-free survival rate [1]. Company Overview - Genprex is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing innovative technologies to deliver disease-fighting genes [1]. - The company's lead product candidate, Reqorsa® Gene Therapy, is being evaluated in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [1]. - Genprex's diabetes gene therapy approach aims to rejuvenate and replenish exhausted beta cells, with ongoing developments in both Type 1 and Type 2 diabetes treatments [2].